CCRC: Effects of Partially Hydrolyzed Whey Peptides (PHWP) On Weight Loss In Individuals With The Metabolic Syndrome (METS)

Completed · Not applicable

Conditions studied: Metabolic Syndrome, Overweight

In brief

The aim of this study is to compare the effects of two different protein supplements (partially hydrolyzed whey protein, PHWP vs. partially hydrolyzed gelatin, PHG) on weight loss in obse individuals with metabolic syndrome (METS). These two supplements will contain equal amounts of protein but differ considerably in their amino acid contents. Whey protein is rich in essential amino acids whereas gelatin is rich in proline. In obese individuals with METS, the hypotheses are: * PHWP will augment fat-mass loss and increase lean-mass to fat-mass ration more than PHG. * PHWP will improve insulin action more than PHG. * PHWP will decrease cardiovascular disease risk more than PHG.

Key facts

Study ID

NCT00739479

Run by

Sidika E. Karakas, MD

People needed

35

Starts

2008-08-01

Expected to finish

2010-08-01

Last updated by the study team

2012-10-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical Diagnoses of Metabolic Syndrome (at least 3/5 of the following)
• Waist Circumference: men: >40 in women: >35 in
• Blood Pressure: >135/>85 mm Hg
• Triglycerides: >150 mg/dl
• HDL-cholesterol: men: <40 mg/dl women: <50 mg/dl
• Fasting Glucose: >100 mg/dl
• Ages 18 to 65 Years
• BMI range of 27 to 42 kg/m\^2
• Body weight <300 lbs
• Weight Stable for 3 Months

You may not qualify if…

• Subjects who habitually consume protein supplements or have eating disorders
• Recent delivery (within 12 months), lactation, pregnancy or intention to become pregnant
• Type 2 diabetes, kidney disease, liver disease, anemia, gout, cancer, untreated thyroid disease, gastrointestinal disease, other metabolic diseases or malabsorption syndromes
• Triglyceride >500 mg/dl, Cholesterol >260 mg/dl
• Use of insulin sensitizers, lipid lowering medication or ACE inhibitors
• Use of anti-obesity medications or supplements for at lease 6 months prior to start of study
• Known allergy or adverse reaction to protein and dairy products (including lactose)

Where it is running

• UC Davis CCRC — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.